Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2022;2453:153–167. doi: 10.1007/978-1-0716-2115-8_10

Immunoglobulin Gene Mutational Status Assessment by Next Generation Sequencing in Chronic Lymphocytic Leukemia.

Anne Langlois de Septenville, Myriam Boudjoghra, Clotilde Bravetti, Marine Armand, Mikaël Salson, Mathieu Giraud, Frederic Davi
PMCID: PMC9761549  PMID: 35622326

Abstract

B cell receptor (BcR) immunoglobulins (IG) display a tremendous diversity due to complex DNA rearrangements, the V(D)J recombination, further enhanced by the somatic hypermutation process. In chronic lymphocytic leukemia (CLL), the mutational load of the clonal BcR IG expressed by the leukemic cells constitutes an important prognostic and predictive biomarker. Here, we provide a reliable methodology capable of determining the mutational status of IG genes in CLL using high-throughput sequencing, starting from leukemic cell DNA or RNA.

Full text of this article can be found in Bookshelf.

References

  1. Hallek M, Shanafelt TD, Eichhorst B (2018) Chronic lymphocytic leukaemia. Lancet 391:1524–1537 doi: 10.1016/S0140-6736(18)30422-7. [DOI] [PubMed]
  2. Chiorazzi N, Stevenson FK (2020) Celebrating 20 years of IGHV mutation analysis in CLL. Hemasphere 4:e334 doi: 10.1097/HS9.0000000000000334. [DOI] [PMC free article] [PubMed]
  3. Sutton LA, Hadzidimitriou A, Baliakas P et al (2017) Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. Haematologica 102:968–971 doi: 10.3324/haematol.2017.165605. [DOI] [PMC free article] [PubMed]
  4. Rossi D, Terzi-di-Bergamo L, De Paoli L et al (2015) Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 126:1921–1924 doi: 10.1182/blood-2015-05-647925. [DOI] [PMC free article] [PubMed]
  5. Fischer K, Bahlo J, Fink AM et al (2016) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127:208–215 doi: 10.1182/blood-2015-06-651125. [DOI] [PubMed]
  6. Hallek M, Cheson BD, Catovsky D et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745–2760 doi: 10.1182/blood-2017-09-806398. [DOI] [PubMed]
  7. Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302:575–581 doi: 10.1038/302575a0. [DOI] [PubMed]
  8. Rajewsky K (1996) Clonal selection and learning in the antibody system. Nature 381:751–758 doi: 10.1038/381751a0. [DOI] [PubMed]
  9. Lefranc MP, Giudicelli V, Duroux P et al (2015) IMGT®, the international imMunoGeneTics information system® 25 years on. Nucleic Acids Res 43:D413–D422 doi: 10.1093/nar/gku1056. [DOI] [PMC free article] [PubMed]
  10. Damle RN, Wasil T, Fais F et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840–1847 [PubMed]
  11. Hamblin TJ, Davis Z, Gardiner A et al (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848–1854 [PubMed]
  12. Stamatopoulos K, Agathangelidis A, Rosenquist R et al (2017) Antigen receptor stereotypy in chronic lymphocytic leukemia. Leukemia 31:282–291 doi: 10.1038/leu.2016.322. [DOI] [PubMed]
  13. Baliakas P, Hadzidimitriou A, Sutton LA et al (2014) Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol 1:e74–e84 doi: 10.1016/S2352-3026(14)00005-2. [DOI] [PubMed]
  14. Sutton LA, Young E, Baliakas P et al (2016) Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica 101:959–967 doi: 10.3324/haematol.2016.141812. [DOI] [PMC free article] [PubMed]
  15. Rosenquist R, Ghia P, Hadzidimitriou A et al (2017) Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia 31:1477–1481 doi: 10.1038/leu.2017.125. [DOI] [PMC free article] [PubMed]
  16. Langerak AW, Brüggemann M, Davi F et al (2017) High-throughput immunogenetics for clinical and research applications in immunohematology: potential and challenges. J Immunol 198:3765–3774 doi: 10.4049/jimmunol.1602050. [DOI] [PubMed]
  17. Davi F, Langerak AW, de Septenville AL et al (2020) Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. Leukemia 34:2545–2551 doi: 10.1038/s41375-020-0923-9. [DOI] [PMC free article] [PubMed]
  18. Brochet X, Lefranc MP, Giudicelli V (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36:W503–W508 doi: 10.1093/nar/gkn316. [DOI] [PMC free article] [PubMed]
  19. Bystry V, Agathangelidis A, Bikos V et al (2015) ARResT/AssignSubsets: a novel application for robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy. Bioinformatics 31:3844–3846 doi: 10.1093/bioinformatics/btv456. [DOI] [PubMed]
  20. Chaudhary N, Wesemann DR (2018) Analyzing immunoglobulin repertoires. Front Immunol 9:462 doi: 10.3389/fimmu.2018.00462. [DOI] [PMC free article] [PubMed]
  21. Giraud M, Salson M, Duez M et al (2014) Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing. BMC Genomics 15:409 doi: 10.1186/1471-2164-15-409. [DOI] [PMC free article] [PubMed]
  22. Duez M, Giraud M, Herbert R et al (2016) Vidjil: a web platform for analysis of high-throughput repertoire sequencing. PLoS One 11:e0166126. [Erratum in: PLoS One (2017) 12:e0172249] doi: 10.1371/journal.pone.0166126. [DOI] [PMC free article] [PubMed]
  23. Bystry V, Reigl T, Krejci A et al (2017) ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data. Bioinformatics 33:435–437 doi: 10.1093/bioinformatics/btw634. [DOI] [PubMed]

RESOURCES